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We propose the hypothesis that soleus muscle function may provide a surrogate measure of 
functional capacity in patients with heart failure. We summarize literature pertaining to skeletal 
muscle as a locus of fatigue and present our recent findings, utilising in vivo imaging in 
combination with biomechanical experimentation and modelling, to reveal novel structure-function 




We propose the hypothesis that soleus function provides a surrogate for functional capacity and 
health status in chronic heart failure. 
 
 






A BRIEF HISTORY OF EXERCISE AND SKELETAL MUSCLE FUNCTION IN 
CHRONIC HEART FAILURE MANAGEMENT 
 
The 11th edition of Harrison's Textbook of Internal Medicine, published in 1987, stated that 
 
treatment of heart failure should  "consist of reducing physical activity, instituting rest and reducing 
afterload.”    By the early 2000's, the American Heart Association concluded that exercise training 
in chronic heart failure (CHF) was     "safe and beneficial overall in improving peak V̇O2, peak 
workload, exercise duration, and parameters of submaximal exercise performance. In addition, 
quality of life improves…." (27).     This statement led other peak bodies to produce 
recommendations such as:     "When medically stable, all CHF patients should be considered for 
referral to an exercise program" (22). 
 
The narrative underlying this paradigm shift is an exemplar of translational research in exercise 
science, with ultimate global impact on patient management. The story has several starting points, 
including: recognition of the importance of peak oxygen uptake (V̇O2 peak) as an index of systemic 
and integrated physiological function that outperforms traditional indices used in prognostication 
and transplant stratification (19), identification of skeletal muscle as an important locus of exercise 
intolerance in heart failure (8), courageous early exercise-training studies illustrating the 
reversibility of such limitations (31), ambitious studies indicating that training could induce 
improvement in outcomes (2) and establishment of the hemodynamic safety of well controlled and 
targeted exercise interventions (3). There are also early examples of patient-centred 
individualisation of exercise prescription utilising novel and targeted approaches (15,17), a trend 




In this brief paper, we revisit and acknowledge the important contributions made by studies that 
indicated that peripheral limitations to performance are amenable to modification in CHF. We also 
present some recent findings using contemporary techniques for the study of skeletal muscle 
function in vivo to pose the novel hypothesis that soleus muscle function may provide a valid 
surrogate measure for functional capacity and health status in patients with chronic heart failure. 
 
THE ONGOING BURDEN OF HUMAN CHRONIC HEART FAILURE 
Chronic heart failure continues to be a major global health burden. Two million new cases of heart 
failure are diagnosed worldwide every year, for an estimated total of 22 million affected. In the US, 
recent data indicate that 5.1 million people are affected by CHF and it is one of the most common 
reasons for hospital admission and general practitioner consultations in the elderly. Despite some 
improvement across recent decades, the mortality rates associated with CHF remain very high, with 
a reported risk-adjusted 1-year mortality of 29.6% in 2008 in the US (4).   
 
CLINICAL RELEVANCE OF THE LOCUS OF THE CLINICAL SYMPTOMS OF 
FATIGUE IN CHRONIC HEART FAILURE 
Poor exercise tolerance is a cardinal symptom of CHF, which significantly impacts upon quality of 
life and the capacity to perform tasks of daily living (6,9). Peak oxygen uptake outperforms ejection 
fraction and hemodynamic indices in terms of prognostication (19) and is used to guide 
transplantation and ventricular assist device implantation (19,20).  
 
Research over the past two decades has identified an intriguing paradox in CHF, in that the primary 
locus of exercise intolerance often lies in the skeletal muscle, rather than the heart itself (7,26). 
Aerobic capacity and resting cardiac function are poorly correlated in patients with CHF (9). 
Instead, peripheral factors including impaired blood flow (17) and skeletal muscle dysfunction (6) 
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have a greater bearing on aerobic capacity and are intrinsically linked to the exercise intolerance in 
this condition. 
 
Recognition of the importance of peripheral abnormalities in CHF led to the “skeletal muscle 
hypothesis” (6), which proposes that activation of muscle ergoreceptors (receptors activated during 
muscle contractions that mediate physiologic adjustments) generate symptoms during exercise and 
that muscle wasting contributes to a wicked cycle of reflex neuro-hormonal activation, peripheral 
vasoconstriction, disease progression and physical inactivity (Figure 1). Consistent with the muscle 
hypothesis, muscle wasting is strongly correlated with reduced aerobic capacity (5) and poor 
prognosis (1). A recent analysis of 200 CHF patients revealed that reduced muscle mass is 
independently associated with lower absolute V̇O2 peak (ml.min-1) when age, sex, ejection fraction 
and co-morbidities were accounted for, and that muscle mass is directly linked to disease 
progression (11). These findings place skeletal muscle function at center-stage when exercise-based 
strategies are devised to target functional limitation in a large proportion of patients with stable 
CHF. 
 
SKELETAL MUSCLE ARCHITECTURE AND MECHANICS IN HUMAN CHRONIC 
HEART FAILURE 
Muscle architecture is closely linked to in vivo muscle mechanics. Muscle volume is one of the 
primary determinants of the muscle’s capacity to generate mechanical work. Maximal muscle force, 
and thus also joint torque production is, on the other hand, more closely associated with muscle 
physiological cross sectional area (PCSA) (29). PCSA is determined by muscle volume, as well as 
fibre length and pennation angle (25). Whilst some studies have examined muscle size in context of 





In addition, two mechanical properties that influence in vivo muscle mechanics independently of 
muscle volume and PCSA are its fiber operating lengths and velocities (force-length and force-
velocity properties). To the best of our knowledge no previous studies have examined fiber length 
and velocity characteristics of skeletal muscle in CHF. It is widely accepted that muscles operating 
outside their optimal length and velocity ranges are severely restricted in their ability to produce 
force, work and power, resulting in loss of function (29). The capacity of muscle to generate 
mechanical work is optimal when it functions over the plateau region of the force-length curve. 
When skeletal muscle operates outside this range (e.g. if muscle fiber lengths are reduced), 
mechanical work and power are drastically compromised. Although abnormalities in CHF skeletal 
muscle structure such as atrophy and a shift to type II fibers (6) and decreased cross-bridge kinetics 
(21) make them susceptible to sub-optimal function, muscle architecture and mechanics as a 
limitation to skeletal muscle function have not previously been studied in CHF.  
 
RECENT STUDIES RELATING PLANTARFLEXOR MUSCLE MORPHOLOGY AND 
FUNCTION TO EXERCISE CAPACITY IN CHRONIC HEART FAILURE  
We recently reported alterations on the functional and morphological properties of the plantarflexor 
muscles in patients affected by CHF (NYHA Class II–IV; ejection fraction < 40 ± 10%; age 62 ± 10 
yr; mean ± SD) (25), relative to control participants matched for age, sex, adiposity and physical 
activity levels. These studies are based on detailed measurements of muscle architecture using state-
of-the art 3D ultrasound imaging (dynamic B-mode imaging coupled with simultaneous motion 
capture of the probe) and estimates of active and passive muscle loads from a novel framework 
incorporating empirical data (dynamic muscle fascicle imaging, electromyography and 
dynamometry) and musculoskeletal modeling. In an effort to maximize accuracy, the derived 
estimates of muscle loads took into account agonist and antagonist muscle actions, muscle-tendon 




Despite a similar overall lower limb lean mass, CHF patients exhibited ~25% lower combined 
triceps surae volume (Fig. 3a) and physiological cross-sectional area (PCSA) (25). These reductions 
in triceps surae size were explained primarily by the marked reductions in the soleus (SOL). A 
strong correlation (r = 0.93) was observed between absolute triceps surae volume and V̇O2 peak in 
CHF patients but not control participants. Furthermore, body mass-specific SOL volume, unlike the 
other triceps surae muscles, correlated strongly with body mass-specific V̇O2 peak in CHF (Figure 
3b). The SOL is a key locomotor and postural muscle in humans and these data, together with a 
strong correlation between body mass-normalized plantarflexor strength and mass-specific V̇O2 
peak in CHF patients (25), raise the possibility that the SOL may be a sentinel skeletal muscle in 
terms of identifying the severity of functional impairment in CHF.  
 
These findings were corroborated (23) by observation that the smaller SOL of CHF patients 
generated lower absolute voluntary active and passive forces (at equivalent levels of passive strain), 
compared to healthy individuals (Figure 4). Importantly, however, this difference was not present 
when the data were normalized by muscle cross-sectional area or volume (Figure 4), nor were the 
normalized active or passive force-length curves different (normalized to optimal fascicle lengths). 
This detailed single muscle analysis suggested to us that the reduced muscle force in CHF may be 
more strongly associated with muscle size than muscle structural, mechanical or bioenergetic 
properties. 
 
Similar findings were observed for the SOL muscle when subjects performed isokinetic 
contractions over the functional ankle range of motion, suggesting a reduction of the total amount of 
mechanical work generated by the muscle fibers in CHF (Figure 5a). Nevertheless, isokinetic 
experiments revealed that the ability of the SOL muscle to produce mechanical work is not 




Notwithstanding the findings outlined above, which tend to implicate SOL muscle size rather than 
intrinsic muscle function as a limitation in CHF, we observed some evidence of altered muscle 
properties in CHF patients. The CHF group exhibited ~20% (p < 0.05) shorter optimal fascicle 
lengths (i.e. the length where peak voluntary isometric force was achieved) as well as shorter 
passive fascicle lengths, compared to the age-matched control group (23). The shorter passive 
fascicle lengths resulted in higher passive force for a given absolute muscle length. It is possible 
that shorter fascicle lengths result in the muscle operating at longer lengths compared to that of 
healthy individuals during functional tasks such as walking.  This could, in turn, result in altered 
force-length-velocity characteristics of the muscle that lead to a reduced force and work capacity. 
Conversely, a shorter optimal fascicle length in CHF might accommodate a more compliant 
Achilles tendon in CHF; which in turn may result from a smaller tendon cross-sectional area (25). 
While the precise mechanisms underlying these characteristics have not been defined, they probably 
reflect a complex interplay between neurohumoral activation, impaired peripheral blood flow and 
reduced activity levels. For example, impaired peripheral blood flow in CHF may have a more 
pronounced effect on distal compared with proximal limb muscles, while the greater reduction in 
SOL muscle volume compared with the medial gastrocnemius may reflect the relative contribution 
to mechanical work among the lower limb muscles during walking (25). This is an intriguing area 
which requires further detailed experimentation.   
 
The morphological and functional abnormalities we report above, particularly in the plantarflexors 
and SOL, could provide a harbinger of impaired function and fatigue (ie initial reduction in the 
contractile capabilities of the muscle with consequent clinical symptoms of fatigue) early in the 
clinical course in CHF. In another recent study (24) we compared the mechanics of walking in CHF 
with that of healthy matched population. Minimal difference in preferred speed or overall joint 
kinematics and kinetics were observed between groups, a finding that may possibly be explained by 
optimization of the mechanical cost of transport (i.e. the amount of mechanical work performed per 
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distance traveled; J.kg-1.m-1). Nevertheless, when normalized to triceps surae volume, a 2-fold 
increase in ankle plantarflexion work was required in CHF. This, together with a greater reliance on 
the ankle to power walking in CHF patients, may contribute to the mechanisms underlying reduced 
exercise capacity and marked fatigability in CHF.  
 
An important caveat related to the studies described above is that they were undertaken in patients 
with heart failure associated with impaired ejection fraction. Further studies are required to establish 
whether a similar relationship exists between aerobic capacity and soleus function in patients with 
heart failure and preserved ejection fraction. 
 
IMPLICATIONS FOR DESIGN OF EXERCISE INTERVENTIONS 
Studies of exercise training have established that the skeletal muscle limitations to function are 
amenable to improvement (7,14,15,17) and that exercise training improves functional capacity, 
cardiovascular mortality (32), hospitalizations (10) and quality of life (35). These benefits typically 
occur in the absence of changes in cardiac function (2,26). The HF-Action trial, which randomised 
2331 heart failure subjects (NYHA II-IV, EF<35%), indicated that, after adjustment for prognostic 
factors, exercise training was associated with a 15% decrease in cardiovascular mortality/CHF 
hospitalizations. It was concluded that “The HF-ACTION study supports a structured exercise 
training program for patients with reduced LV function and HF symptoms in addition to evidence-
based therapy” (32). However, few attempts have been made to address the question of which 
exercise prescription will optimise outcomes in HF. Commentary relating to the HF-ACTION trial 
included “The one thing this trial does not show is what type of exercise to advocate" (32). 
 
Logically, interventions that present the muscle with an intense stimulus, whilst minimizing 
cardiovascular burden, have the potential to amplify functional gains whilst minimizing acute 
exercise risk. In accordance with this theoretical framework, we developed in the 1990’s 
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individually tailored circuit weight training (CWT) programs focusing on isolated muscle groups 
and based on comprehensive a priori exercise testing (15,17). Because the exercises were 
performed on isolated muscle groups at any one time, the intensity of effort was relatively high, 
whilst the cardiovascular burden was modest (3,13). We also successfully established the 
physiological benefits of such programs in other clinical conditions in a series of experiments 
(16,33,34).  These studies were among the first to utilize resistance modalities in CHF and they 
directly informed the development of new exercise strategies which are now recognized 
internationally (27). This work has also directly translated into changes in the management of CHF 
in Australia and elsewhere (30).  
 
Despite advances in knowledge and clinical practice which have resulted from the development of 
individually-tailored exercise interventions aimed at reversing physiological limitations in CHF, no 
previous study has specifically devised exercise training programs based on ameliorating deficits in 
muscle mechanics (e.g. muscle architecture including muscle length, and mechanical force and 
work capacities). This is surprising, given the accepted importance in CHF of abnormalities in 
length tension relationships of cardiac myocytes (i.e. Frank-Starling impacts) and also because of 
the proven benefits of training interventions focussed on improving muscle mechanics in subjects 
with other forms of skeletal myopathies (28). The questions that now emerge, include “How can 
exercise training interventions that specifically target limitations in muscle mechanics be designed 
for large cohorts of patients, in a manner that is time efficient, tolerable and effective?” This is a 
future challenge for researchers in the domain of clinical cardiovascular exercise science.   
 
IMPLICATIONS FOR CLINICAL SURVEILLANCE 
Cardiorespiratory fitness (VO2peak testing) is routinely assessed in patients with CHF due to its 
strong prognostic value (18). Such tests are expensive and require a high degree of operator 
expertise and training.  The close relationship observed between soleus muscle function and aerobic 
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capacity in patients with CHF makes a case for the serial assessment of soleus muscle function for 
monitoring changes in clinical status over time. While the studies cited in this review have 
employed isokinetic dynamometry, protocols to assess soleus muscle strength and endurance that 
utilise resistance exercise equipment routinely available in cardiac rehabilitation programs could 
quite easily be developed. Similarly, we have developed non-invasive ultrasound-based approaches 
to the quantification of the volume of the triceps surae (25) which are cheap and suitable for use in 
patients with implanted devices, who are MRI contraindicated.  Such assessments would logically 
be conducted by exercise specialists, with results conveyed to medical staff to support clinical 
surveilance.  The degree to which changes in soleus and other skeleletal muscle size and function 
relate to, or predict, changes in clinical status should form the basis of future research to test and 





Skeletal muscle function is an important locus of the clinical symptoms of fatigue in heart failure, 
with implications related to survival, stratification for transplant and ventricular assist device 
implantation.  In order to optimise exercise training for subjects with chronic heart failure, the 
limitations to performance must first be fully understood. Taken together, our recent studies of the 
skeletal muscle mechanics of patients with CHF suggest that abnormalities in the triceps surae. In 
particular the SOL appears to be particularly susceptible to the muscle wasting and impaired aerobic 
capacity which characterize CHF. They also highlight a link between the morphological and 
functional alterations of the calf muscles and fatigue experienced during walking in CHF. Our 
recent integrated muscle-level and functional gait analyses indicate that reversing these limitations 
may depend foremost on restoring muscle size, although muscle functional characteristics (in 
particular muscle length) may play a further important role. Abnormalities in soleus muscle volume 
and function may provide a sentinel for detection of early decompensation and a target for 
specifically designed interventional strategies, although further work is required to develop 3D 
ultrasound approaches. It is conceivable that, in time, assessment of triceps surae volume and 
function will become more feasible\ and cheaper with less user dependence. We hope that this brief 
review raises useful hypotheses for future studies aimed at individualised detection of disease 
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Figure 1.  Model depicting the impact of peripheral limitations in chronic heart failure (CHF) based 
on (6). Abnormalities in skeletal muscle limit exercise capacity and exacerbate 
symptoms. Personalized exercise prescription is proposed as a means to reverse the 
progression of the disease by acting on three different pathways influencing skeletal 
muscle health, namely the muscles’ morphological and architectural properties, their 
mechanical properties, and their functional characteristics during movement. 
 
Figure 2.  Schematic showing analytical framework for assessing skeletal muscle morphology, 
mechanical properties and function including experimental and modeling approaches. 
Active and passive joint torque and joint range of motion assessed by dynamometry (a). 
B-mode ultrasound techniques to assess muscle fascicle lengths and pennation angles 
dynamically (image depicts the soleus muscle) (b); three-dimensional architecture 
including individual muscle volume and physiological cross-sectional area (image depicts 
the individual muscles of the triceps surae) (c); and tendon moment arms using a 
combination of muscle imaging and optical tracking of joint centers (d). Surface 
electromyography to assess muscle excitation and activation of agonist and antagonist 
muscles (e).  Experimental data (a-e) form the basis for subject-specific musculoskeletal 
models (OpenSim) (f) that permit further assessment of muscle properties and function 
including estimates of individual peak active muscle force and passive muscle force. 
 
Figure 3. Triceps surae volume (a) and relationship between SOL muscle volume and aerobic 
capacity (b).  The chronic heart failure (CHF) group is displayed in grey the control 





Figure 4. Absolute peak voluntary force production (a) and normalized absolute peak voluntary 
force production (b). The chronic heart failure (CHF) group is displayed in grey bars, and 
the control group in black bars. Data are means ± S.D.; * designates a significant 
difference (p < 0.05) between the CHF and the control group.  
 
Figure 5. Work produced by the plantarflexors (a) and work produced by the plantarflexors 
normalized by SOL muscle volume obtained in isokinetic condition (5°/s) (b). The 
chronic heart failure (CHF) group is displayed in grey bars, and the control group in 
black bars. Data are means ± S.D. This figure was created originally by the authors and 
has not been previously published. 
 
